Menu Search
Equities

DarioHealth Corp

DRIO:NAQ

DarioHealth Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.8299
  • Today's Change0.050 / 6.40%
  • Shares traded44.58k
  • 1 Year change-20.20%
  • Beta1.5110
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for DarioHealth Corp have a median target of 3.50, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate represents a 321.74% increase from the last price of 0.8299.
High502.5%5.00
Med321.7%3.50
Low141.0%2.00

Earnings history & estimates in USD

On Nov 07, 2024, DarioHealth Corp reported 3rd quarter 2024 losses of -0.25 per share. This result exceeded the -0.270 consensus loss of the 3 analysts covering the company and exceeded last year's 3rd quarter results by 48.98%.
The next earnings announcement is expected on Mar 20, 2025.
Average growth rate-23.64%
DarioHealth Corp reported annual 2023 losses of -1.93 per share on Mar 28, 2024.
Average growth rate+27.50%
More ▼

Revenue history & estimates in USD

DarioHealth Corp. had 3rd quarter 2024 revenues of 7.42m. This bettered the 7.40m consensus of the 3 analysts covering the company. This was 5.05% above the prior year's 3rd quarter results.
Average growth rate+22.33%
DarioHealth Corp. had revenues for the full year 2023 of 20.35m. This was 26.41% below the prior year's results.
Average growth rate+44.85%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.